Skip to main content

Table 2 The National Eye Institute 39-Question Visual Function Questionnaire composite and subscale scores divided by treatment group

From: Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis

  Group 1 Group 2
Median P value Median P value
VFQ-25 Subscales BL
( n= 13)
M6
( n= 13)
M12
( n= 12)
BL-M6 BL-M12 BL
( n= 13)
M6
( n= 13)
M12
( n= 11)
BL-M6 BL-M12
General health 73.08 73.08 71.43 1.00 0.80 66.21 70.33 71.75 0.47 0.30
General vision 59.49 70.77 72.78 0.03 0.04 65.13 70.00 70.61 0.18 0.70
Ocular pain 78.85 79.81 88.54 0.79 0.01 67.31 84.62 84.09 0.01 0.01
Near activities 66.35 67.69 76.18 0.73 0.03 73.59 74.74 73.64 0.78 0.56
Distance activities 73.33 79.17 83.96 0.15 0.04 74.36 80.29 78.41 0.12 0.23
Vision-specific social functioning 85.26 89.10 95.49 0.44 0.03 89.74 93.59 92.42 0.31 0.28
Vision-specific mental health 59.68 68.08 78.33 0.07 0.01 59.23 70.77 74.09 0.02 0.06
Vision-specific role difficulties 71.63 75.48 85.42 0.42 0.04 69.71 76.92 80.11 0.07 0.22
Vision-specific dependency 80.29 87.02 92.71 0.16 0.07 85.58 88.94 92.61 0.38 0.26
Drivinga 79.63 81.48 80.21 0.56 0.52 64.58 72.22 70.00 0.08 0.54
Color vision 88.46 94.23 95.83 0.39 0.10 92.31 96.15 93.18 0.44 1.00
Peripheral vision 78.85 81.73 83.33 0.69 0.19 78.85 83.65 75.00 0.41 0.34
Composite score for VFQ-39 (VFQ-25 + additional items) 73.87 78.64 84.87 0.06 0.01 74.67 81.17 80.49 0.03 0.10
  1. Italicized values indicate statistical significance.
  2. aDriving (group 1): n = 9 for BL-M6 and n = 8 for BL-M12 comparison. Driving (group 2): n = 12 for BL-M6 and n = 10 for BL-M12 comparison.
  3. BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire.